Literature DB >> 16824601

Clonal repertoire diversification of a neutralizing cytomegalovirus glycoprotein B-specific antibody results in variants with diverse anti-viral properties.

Yvelise Barrios1, Susanne Knör, Johan Lantto, Michael Mach, Mats Ohlin.   

Abstract

Cytomegalovirus induces a chronic infection that in normal individuals is controlled by the immune system. In the case of humoral immunity, epitopes, in particular antigenic domain-1, in glycoprotein B have proven to be important for the induction of virus-neutralizing activity. Such antibodies can exert potent virus-neutralizing activity but can also block neutralizing antibodies from binding. Furthermore, these antibodies differ in their fine recognition of antigenic domain-1 as determined by epitope mapping. By using combinatorial library and phage display technologies we have now isolated a large array of clonally related antibody fragments to understand the origin of this diversity. This procedure allowed us to demonstrate that much of the diversity in functional activity (virus neutralization) and epitope recognition can arise from a single parental molecule through somatic mutation processes. We have thus demonstrated that the clonal diversification of a single antigen-specific clone can account for much of the diversity in antibody anti-viral activity. These findings have implications on the development of a gB-based subunit vaccine, as an effective vaccine preparation need not only to recruit appropriate clones into the immune response but also to evolve them properly so as to maintain an appropriate biological function.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16824601     DOI: 10.1016/j.molimm.2006.04.024

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  5 in total

Review 1.  Human cytomegalovirus infection and antiviral immunity in septic patients without canonical immunosuppression.

Authors:  Lutz von Müller; Thomas Mertens
Journal:  Med Microbiol Immunol       Date:  2008-03-08       Impact factor: 3.402

2.  Chimeric Antigen Receptors Targeting Human Cytomegalovirus.

Authors:  Ayub Ali; Flavia Chiuppesi; Minh Nguyen; Mary Ann Hausner; Jenny Nguyen; Mindy Kha; Angelina Iniguez; Felix Wussow; Don J Diamond; Otto O Yang
Journal:  J Infect Dis       Date:  2020-08-04       Impact factor: 5.226

3.  Rapid discovery and optimization of therapeutic antibodies against emerging infectious diseases.

Authors:  J Rogers; R J Schoepp; O Schröder; T L Clements; T F Holland; J Q Li; J Li; L M Lewis; R P Dirmeier; G J Frey; X Tan; K Wong; G Woodnutt; M Keller; D S Reed; B E Kimmel; E C Tozer
Journal:  Protein Eng Des Sel       Date:  2008-05-13       Impact factor: 1.650

4.  Whole CMV proteome pattern recognition analysis after HSCT identifies unique epitope targets associated with the CMV status.

Authors:  Lena Pérez-Bercoff; Davide Valentini; Simani Gaseitsiwe; Shahnaz Mahdavifar; Mike Schutkowski; Thomas Poiret; Åsa Pérez-Bercoff; Per Ljungman; Markus J Maeurer
Journal:  PLoS One       Date:  2014-04-16       Impact factor: 3.240

5.  A neutralizing anti-gH/gL monoclonal antibody is protective in the guinea pig model of congenital CMV infection.

Authors:  Marcy R Auerbach; Donghong Yan; Rajesh Vij; Jo-Anne Hongo; Gerald Nakamura; Jean-Michel Vernes; Y Gloria Meng; Samantha Lein; Pamela Chan; Jed Ross; Richard Carano; Rong Deng; Nicholas Lewin-Koh; Min Xu; Becket Feierbach
Journal:  PLoS Pathog       Date:  2014-04-10       Impact factor: 6.823

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.